ADMA Biologics Quarterly Balance Sheet
NASDAQ: ADMAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
ADMA Biologics financial position
As of Jun 30, 2026, ADMA Biologics reported total assets of $684.2 million, up 22.5% from a year earlier against total liabilities of $276.0 million. Shareholders' equity stood at $408.2 million, or 59.7% of assets. The company held $136.0 million in cash and equivalents against $196.6 million of debt, a net debt position of $60.6 million.
The current ratio (current assets divided by current liabilities) was 6.97, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.48.
Summary generated from market data by MetaCap's automated system. Methodology
ADMA Biologics balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 136.02M | 138.15M | 87.63M | 61.38M | 90.28M | 71.63M | 103.15M | 86.71M | 88.24M | 45.33M | 51.35M | 74.16M |
| Receivables | 138.23M | 135.86M | 158.43M | 137.67M | 109.73M | 99.41M | 50.00M | 50.14M | 30.11M | 49.62M | 27.42M | 31.32M |
| Inventory | 239.31M | 222.10M | 206.47M | 196.67M | 191.46M | 172.19M | 170.24M | 171.80M | 179.81M | 177.73M | 172.91M | 163.12M |
| Total Current Assets | 528.20M | 511.17M | 466.51M | 402.65M | 399.56M | 351.81M | 331.41M | 318.19M | 303.69M | 276.42M | 257.01M | 273.70M |
| Property, Plant & Equipment | 66.66M | 65.01M | 65.06M | 69.51M | 57.50M | 57.71M | 54.71M | 53.69M | 54.33M | 55.32M | 53.84M | 54.81M |
| Goodwill | 3.53M | 3.53M | 3.53M | 3.53M | 3.53M | 3.53M | 3.53M | 3.53M | 3.53M | 3.53M | 3.53M | 3.53M |
| Intangible Assets | 575.00K | 630.00K | 632.00K | 491.00K | 527.00K | 452.00K | 460.00K | 485.00K | 479.00K | 321.00K | 499.00K | 476.90K |
| Total Assets | 684.21M | 665.18M | 624.24M | 568.69M | 558.38M | 510.57M | 488.68M | 390.62M | 376.40M | 350.88M | 329.18M | 349.00M |
| Accounts Payable | 31.72M | 20.52M | 22.52M | 24.02M | 29.77M | 20.61M | 20.22M | 16.02M | 14.18M | 17.19M | 15.66M | 10.85M |
| Short-Term Debt | 3.75M | 3.28M | 2.81M | 2.34M | — | — | 0 | — | — | — | — | — |
| Total Current Liabilities | 75.76M | 73.54M | 69.54M | 56.49M | 74.94M | 53.50M | 55.54M | 44.89M | 44.18M | 53.09M | 49.81M | 41.84M |
| Long-Term Debt | 192.84M | 193.58M | 69.33M | 70.08M | 73.40M | 72.53M | 72.34M | 101.33M | 131.07M | 130.85M | 130.59M | 142.03M |
| Total Liabilities | 276.00M | 274.86M | 146.92M | 137.50M | 160.06M | 137.15M | 139.66M | 158.73M | 188.13M | 197.17M | 193.98M | 197.56M |
| Shareholders' Equity | 408.21M | 390.32M | 477.32M | 431.19M | 398.32M | 373.42M | 349.02M | 231.89M | 188.27M | 153.71M | 135.21M | 151.44M |
| Retained Earnings | -78.50M | -116.33M | -161.65M | -211.03M | -247.46M | -281.68M | -308.58M | -420.48M | -456.39M | -488.45M | -506.26M | -488.61M |
| Total Debt | 196.59M | 196.87M | 72.14M | 72.43M | 73.40M | 72.53M | 72.34M | 101.33M | 131.07M | 130.85M | 130.59M | 142.03M |
| Net Cash (Debt) | -60.57M | -58.71M | 15.49M | -11.04M | 16.89M | -902.00K | 30.81M | -14.62M | -42.83M | -85.52M | -79.24M | -67.87M |
| Shares Outstanding | 225.36M | 232.29M | 237.87M | 238.33M | 238.57M | 238.53M | 236.62M | 236.38M | 233.03M | 231.77M | 226.06M | 225.96M |
This table shows 12 quarterly periods of ADMA Biologics's balance sheet, from Q2 2026 back to Q3 2023, across 19 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow ADMA's reporting calendar. What is a balance sheet?